![David McAvoy](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David McAvoy
Consigliere Generale presso TEVA PHARMACEUTICAL INDUSTRIES LIMITED
Patrimonio netto: 15 552 $ in data 30/06/2024
Posizioni attive di David McAvoy
Società | Posizione | Inizio | Fine |
---|---|---|---|
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Consigliere Generale | 01/03/2024 | - |
Villages of Indiana | Direttore/Membro del Consiglio | - | - |
Storia della carriera di David McAvoy
Precedenti posizioni note di David McAvoy
Società | Posizione | Inizio | Fine |
---|---|---|---|
FRESH TRACKS THERAPEUTICS, INC. | Responsabile della Conformità | 01/01/2019 | 01/09/2023 |
Consigliere Generale | 01/01/2019 | 01/09/2023 | |
ELI LILLY AND COMPANY | Corporate Officer/Principal | - | - |
Vical, Inc.
![]() Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Responsabile della Conformità | 31/08/2019 | - |
Consigliere Generale | 31/08/2019 | - | |
Brickell Subsidiary, Inc.
![]() Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO. | Responsabile della Conformità | 01/01/2019 | - |
Consigliere Generale | 01/01/2019 | - | |
ENDOCYTE, INC. | Responsabile della Conformità | 01/01/2018 | - |
Consigliere Generale | 01/01/2018 | - |
Formazione di David McAvoy
Indiana University | Graduate Degree |
University of Notre Dame | Undergraduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 9 |
Israele | 2 |
Posizioni
General Counsel | 5 |
Compliance Officer | 4 |
Graduate Degree | 1 |
Settori
Health Technology | 7 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
FRESH TRACKS THERAPEUTICS, INC. | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
Aziende private | 4 |
---|---|
Endocyte, Inc.
![]() Endocyte, Inc. Pharmaceuticals: MajorHealth Technology Endocyte, Inc. engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN. | Health Technology |
Villages of Indiana | |
Vical, Inc.
![]() Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Brickell Subsidiary, Inc.
![]() Brickell Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology Brickell Subsidiary, Inc. operates as a clinical-stage pharmaceutical company. It focuses on the development of differentiated, innovative drug therapies for the treatment of skin diseases. The firm specializes in Hyperhidrosis, Cutaneous T-Cell Lymphoma and Psoriasis areas. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in November 2009 and is headquartered in Boulder, CO. | Health Technology |
- Borsa valori
- Insiders
- David McAvoy
- Esperienza